Also known as EGFR and HER1.
Final overall survival data for RYBREVANT plus chemotherapy in EGFR exon 20 insertions and tolerability updates for subcutaneous RYBREVANT FASPRO with prophylactic strategies.
Selpercatinib significantly reduces disease recurrence risk in early-stage RET fusion-positive NSCLC. Safety profile aligns with previous trials. Detailed results pending.
Amivantamab with chemotherapy shows promising results in metastatic colorectal cancer, maintaining responses beyond two years and addressing resistance to current therapies.
Petosemtamab shows promising response rates in 1L and 2L mCRC, with potential as a new standard of care.
Takeda gains rights to two late-stage cancer drugs and an option for an early-stage program, focusing on global development and commercialization outside Greater China.
Petosemtamab data in metastatic colorectal cancer to be presented in plenary and poster sessions at an upcoming conference.
